Introduction
S tem cells play a key role in embryonic development, organogenesis, and tissue regeneration in adults. 1 Because of their self-renewal potential and ability to differentiate toward various lineages, stem cells have become a key component of tissue engineering approaches. Among the numerous stem cell sources currently studied for their application in regenerative medicine, one can include muscle-derived stem cells (MDSCs). It is an early myogenic progenitor cell that has been isolated from the mouse skeletal muscle using a modified preplate technique. 2, 3 MDSCs have the ability to differentiate toward skeletal muscle, neural, endothelial, and hematopoietic tissues, 3, 4 and when treated with bone morphogenetic protein 2 (BMP2) or BMP4, MDSCs are capable of osteogenic and chondrogenic differentiation in vitro, have been used for bone and cartilage formation in vivo, and show promise in the developing field of bone and cartilage tissue engineering. [5] [6] [7] [8] [9] To undergo cellular differentiation toward a specific lineage, all cells require the involvement of intrinsic signaling pathways, which can be activated by extrinsic signals, such as growth factors. BMPs are biological factors that play a key role in the osteogenic and chondrogenic differentiation of numerous cells in vitro and in vivo. The main BMP signaling pathway utilizes signaling molecules known as Smads, [10] [11] [12] although BMPs have been also shown to utilize other cell signaling pathways such as the mitogen-activated protein kinase (MAPK) cascades and the phosphatidyl inositol 3-kinase (PI3K). [13] [14] [15] [16] [17] [18] [19] [20] [21] Inhibitory compounds have been widely used to elucidate the role of the pathways they inhibit. Some of these compounds are pyridinyl imidazole (SB203580) and 2 0 -amino-3 0 -methoxyflavone (PD98059), which are inhibitors of the MAPK cascades, 22, 23 and 2-(4-morpholinyl)-8-phenylchromone (Ly294002), which inhibits the PI3K pathway. 24 SB203580 specifically inhibits the MAPK family member known as stress-activated protein kinase 2a, also known as p38. 23 PD98059 binds to MAPK kinase 1 (MEK1), preventing its activation by upstream proteins such as Raf, which makes it unable to phosphorylate extracellular signal-regulated kinases (ERK1/2). 22 SB203580 thus inhibits the p38 MAPK pathway, and PD98059 inhibits the ERK1/2 pathway. Ly294002 binds to the ATP-binding site of PI3K, preventing it from phosphorylating Akt and thus inhibiting the PI3K-Akt pathway. 24 The p38 MAPK pathway has been linked to osteogenesis in cell types such as human osteoblastic cells, 25, 26 mouse MC3T3-E1 preosteoblastic cells, 27, 28 and mouse C2C12 cells. 14, 29 Gallea et al. showed that both the p38 MAPK and ERK1/2 cascades are activated by stimulation of C2C12 cells with BMP2.
14 In this specific cell line, blocking the p38 MAPK pathway with SB203580, a p38-specific inhibitor, led to a dose-dependent decrease in alkaline phosphatase (ALP) activity, whereas inhibition of the ERK1/2 cascade by its selective inhibitor PD98059 led to a slight increase in ALP activity. The PI3K-Akt pathway has been also implicated in the differentiation of osteoblasts, myoblasts, chondrocytes, and adipocytes. 15, [30] [31] [32] [33] [34] BMP2 can stimulate PI3K activity in osteogenic cells and its inhibition with the specific inhibitor Ly294002 prevented BMP2-induced ALP activity.
15
BMP2 and BMP4 are highly homologous molecules, differing solely in their amino terminal region. Both can bind to BMP receptors type I and type II, which come together to enable BMP receptor type II to phosphorylate BMP receptor type I, leading to Smad activation. 10, 35 Although many cell signaling studies have been performed with BMP2 stimulation, inhibitors such as PD98059, SB203580, or Ly294002 have been also studied using BMP4. 20, 21, 28, [36] [37] [38] It has been shown that BMP4-stimulated osteocalcin synthesis is negatively regulated by ERK1/2, whereas p38 MAPK is a positive regulator of its synthesis in MC3T3-E1 cells.
36 BMP4-induced ALP activity can be reduced in the same cells with SB203580, also suggesting an important role of p38 MAPK in BMP4-induced osteogeneis. 28 Using Ly294002 on human multipotent mesenchymal stromal cells (MSCs), it was determined that the PI3K pathway may play an important role in endogenous BMP osteogenesis. 21 To date, the signaling pathways involved in the BMP4-induced osteogenic differentiation of MDSCs are not well known. Elucidating the role of specific signaling pathways in the BMP4-induced osteogenic differentiation of MDSCs may allow for increased regulation of differentiation, which may in turn lead to novel approaches to improve the role of MDSCs for bone tissue engineering. Therefore, this study tested the hypothesis that ERK1/2, p38 MAPK, and PI3K pathways affect BMP4-induced osteogenic differentiation of MDSCs by playing a role in their cell viability, expression of osteoblast-related genes, ALP activity, and tissue mineralization.
Experimental Procedures

Isolation and culture of MDSCs
MDSCs were isolated from 3-week-old C57BL/10J mice using a modified preplate technique. 2, 3 Cells were cultured in phenol red-free proliferation medium (PM) consisting of Dulbecco's Modified Eagle Medium (DMEM) (Invitrogen) supplemented with 110 mg/L sodium pyruvate (SigmaAldrich), 584 mg/L l-glutamine, 10% fetal bovine serum, 10% horse serum, 1% penicillin/streptomycin (all from Invitrogen), and 0.5% chick embryo extract (Accurate Chemical Co.) at 378C in a humidified atmosphere of 5% CO 2 in air. To determine the minimal dose of BMP4 necessary to have an effect on ALP activity and Alp gene expression, MDSCs were plated at a density of 1500 cells/cm 2 and, on the following day, were treated with BMP4 (0, 50, 100, or 200 ng/mL). All subsequent monolayer assays in this study began with cells plated at a density of 1500 cells/cm 2 and, on the following day, were treated with or without the optimized concentration of BMP4 (50 ng/mL) and the inhibitors PD98059 (Biomol International), SB203580 (Biomol International), or Ly294002 (Cell Signaling), which are specific inhibitors for the ERK1/2, p38 MAPK, and PI3K pathways, respectively. Inhibitors were dissolved in dimethyl sulfoxide before use, and control cultures received a concentration of 25 mM of dimethyl sulfoxide, which is equivalent to the highest concentration found in the treated cultures. In all assays, cells were incubated with the inhibitors for 1 h before addition of BMP4.
Cell viability
Cell viability was measured in 96-well microtiter flatbottomed plates. Inhibitors were tested at concentrations of 25 mM (PD98059 and SB203580) or 10 mM (Ly294002) and medium was refreshed every 48 h (100 mL/well). The inhibitor concentrations were chosen based on previously published studies 14, 17 and preliminary data. Cell viability was assayed with the CellTiter 96 Ò AQueous One Solution Cell Proliferation Assay (Promega) after 4 days of treatment. At the end of the assay, 20 mL of CellTiter 96 Ò AQueous One Solution reagent was added to each well, the plate was incubated for 2 h at 378C in a humidified, 5% CO 2 incubator, and the absorbance was measured at 490 nm.
Quantitative polymerase chain reaction analysis of osteogenic genes MDSCs were treated as described above for 24 h, after which total RNA was collected using the RNeasy kit (Qiagen). Quantitative real-time PCR (qPCR) analysis was performed with Taqman Ò One-step RT-PCR Master Mix (Applied Biosystems) as described previously. 39 RNA samples (1 mL) were added to sequence-specific primers and Taqman Ò probes (200 nM per 10 mL reaction) for Alp, Runx2, and Osterix (Osx) genes. All target genes were normalized to 18S (primers and probe from Applied Biosystems). The sequences of the target gene primers and probes were previously published. 39 All target gene probes were labeled with FAM as the 5 0 reporter dye and TAMRA as the 3 0 quencher dye. qPCR assays were carried out in triplicate on an ABI Prism 7900HT sequence detection system in the core facility of the Genomics and Proteomics Core Laboratories of the University of Pittsburgh. Data were analyzed using SDS 2.1 Software from Applied Biosystems.
ALP activity
For ALP enzymatic activity, MDSCs were treated with BMP4 in the presence or absence of the inhibitors PD98059 (25 mM), SB203580 (25 mM), or Ly294002 (10 mM), as described above. Three days after initiation of treatment, the cells were washed once with phosphate-buffered saline, lysed in 0.1% 3648 PAYNE ET AL.
Triton-X in water, and assayed using SIGMA FASTÔ p-nitrophenyl phosphate tablets (N-2770; Sigma-Aldrich). Diluted samples of cell lysate were incubated with p-nitrophenyl for 30 min in the dark at room temperature. Following this incubation, absorbance at 405 nm was determined. Total protein was also calculated by assaying diluted samples of cell lysate using the Micro BCAÔ protein assay (Pierce) according to manufacturer's instructions. ALP activity was normalized per mg protein and expressed as nanomoles of p-nitrophenyl liberated per microgram of total cellular protein.
Osteogenic pellet culture
To test mineralization, 250,000 MDSCs were cultured as pellets, as previously described, 40 in osteogenic medium (OSM) containing phenol red-free DMEM supplemented with 110 mg/L sodium pyruvate, 584 mg/L l-glutamine, 10% fetal bovine serum, 1% penicillin/streptomycin, 10 À7 M dexamethasone, 5Â10
À5 M ascorbic-acid-2-phosphate, and 10 À2 M b-glycerophosphate and with BMP4 (100 ng/mL) in the presence or absence of pathway inhibitors (25 mM PD98059, 25 mM SB203580, and 10 mM Ly294002) for 21 days. Medium was replaced every 3 days. Preliminary data testing different doses of BMP4 on pellet cultures indicated that BMP4 at a concentration of 100 ng/mL was necessary to induce a measurable amount of mineralization in the MDSC population used in this study. To assess mineralization, all pellets were analyzed at 14 and 21 days using a mCT imaging system (vivaCT 40; Scanco Medical) with the following settings: 55 kVp of energy, 200 ms integration time, and an isotropic voxel size of 10.5 mm.
40 Two-dimensional image slices were obtained and contour lines were drawn to define the volume of interest. An appropriate threshold was chosen for the bone voxels by visually matching thresholded areas to grayscale images. The threshold was kept constant throughout the analyses of each pellet. This led to a threedimensional (3D) reconstruction of the mineralized tissue within the pellets and provided quantitative data on mineralized tissue volume (mm 3 ) and density (mg hydroxyapatite [HA]/cm 3 ). In a subsequent experiment, pellets were made and treated with BMP4 for 21 days, but were only treated with pathway inhibitors for the first 7 days of culture.
Statistical analysis
All in vitro monolayer experiments (cell viability, qPCR, and ALP activity) were performed in triplicate and repeated three times. One representative experiment is reported as the mean of three treatment replicates AE standard error of mean. For osteogenic pellet culture experiments, data represent four pellets per treatment group. Data for Figures 1, 2, 4 , and 5 were analyzed using a one-way, between-subjects analysis of variance and Tukey post hoc analysis. Data for Figure 3 were analyzed using Student's t-tests for each comparison (with and without inhibitor). Data for Figure 6 were analyzed using separate (for volume and density, respectively) two-way, within-subject analysis of variance and Tukey post hoc analysis. All analyses were performed with SPSS statistical software. A p-value of <0.05 was considered significant.
Results
Response of MDSCs to BMP4 stimulation
Twenty-four hours after the initiation of BMP4 treatment (50, 100, or 200 ng/mL), a dose response was observed for Alp gene expression and ALP activity. Both were significantly higher than untreated control at all BMP4 concentrations tested (Fig. 1a , b, *p < 0.05). The lowest BMP4 concentration necessary to have a significant effect on MDSCs, 50 ng/mL, was chosen for all other assays involving monolayer culture.
Effect of pathway inhibitors on cell viability
Specific inhibitors to the ERK1/2, p38 MAPK, and PI3K pathways were added to untreated (control) or BMP4-treated MDSCs and the cell viability was measured after 4 days (Fig.  2) . Cell viability was not significantly increased in BMP4-treated cells compared with untreated control cells. Inhibition of the ERK1/2 pathway had no effect on the viability of MDSCs (Fig. 2a) , and inhibition of the p38 MAPK pathway similarly did not affect MDSC viability (Fig. 2b) . Inhibition of the PI3K pathway in MDSCs displayed a significant decrease in cell viability and this was evident when both control cells and BMP4-treated cells were incubated with the pathway inhibitor (Fig. 2c, * 
Effect of pathway inhibitors on osteogenic differentiation
Osteogenic gene expression. Inhibition of the ERK1/2 pathway by addition of PD98059 to BMP4-treated MDSCs did not show a significant effect on Alp, Runx2, or Osx gene expression (Fig. 3a) . However, a trend of increased fold change over BMP4 treatment only was observed for both Alp and Runx2 gene expression (Fig. 3a) . A significant decrease in Alp gene expression was seen as a result of inhibiting the p38 MAPK pathway during BMP4 stimulation (Fig. 3b , *p < 0.05). A decrease in Osx gene expression upon addition of SB203580 to BMP4 was also observed, as levels were nondetectable by qPCR (Fig. 3b, N/D) . Following inhibition of the PI3K pathway with Ly294002, an increase in Alp, Runx2, and Osx gene expression was observed in comparison to BMP4 treatment only (Fig. 3c) . This increase was statistically significant for Runx2 and Osx gene expression (Fig. 3c, *p < 0.05) .
ALP activity. Inhibition of the ERK1/2 pathway led to a significant increase in ALP activity in MDSCs that were treated with BMP4 (Fig. 4 , *p < 0.05 vs. BMP4). The opposite was seen with inhibition of the p38 MAPK pathway, where a significant decrease in ALP activity was found (Fig. 4 , *p < 0.05 vs. BMP4). Inhibition of the PI3K pathway in BMP4-treated MDSCs significantly decreased ALP activity (Fig. 4 , *p < 0.05 vs. BMP4).
Mineralization. Cell pellets are shown in Figure 5a . From macroscopic observation, pellets cultured with BMP4 and the inhibitor to either the ERK1/2 or the PI3K pathway appear less translucent than pellets that received BMP4 only or BMP4 and the inhibitor to the p38 MAPK pathway. These (Fig. 5c) .
To determine whether a sustained inhibition of the pathways was necessary to affect mineralization, pellets were treated with BMP4 for the 21-day duration of the experiment, but were treated with inhibitors to specific pathways for only the first 7 days of culture. mCT analysis showed that the pellets that received the inhibitor to the ERK1/2 pathway for 7 days had significantly greater mineralized tissue volume and density than the pellets that were treated with BMP4 only, and this increase remained after 21 days of pellet culture (Fig. 6a , b, *p < 0.05 vs. OSM þ BMP4). Inhibition of the p38 MAPK pathway for the first 7 days of pellet culture showed a significant decrease in mineralized tissue volume and density compared with BMP4 treatment only at 14 days (Fig. 6a , b, *p < 0.05 vs. OSM þ BMP4). Interestingly, there was a significant increase in mineralization in this group between 14 and 21 days of culture, making it no longer different from control (Fig. 6a, b, # p < 0.05 vs. 14 days). Unlike continuous inhibition of the PI3K pathway for 21 days, inhibition of this pathway for only the first 7 days of pellet culture did not lead to differences in mineralized tissue volume or density compared with the pellets treated with BMP4 only (Fig. 6a, b) .
A summary of all these results has been included in Table 1 to provide an overview of the effect of each pathway on the osteogenic differentiation of MDSCs.
Discussion
In this study, the BMP4 signaling of MDSCs was characterized by studying an MDSC population that readily undergoes osteogenic differentiation when treated with BMP4. By taking advantage of specific chemical inhibitors to the ERK1/2, p38 MAPK, and PI3K pathways, such as PD98059, SB203580, and Ly294002, respectively, it was possible to elucidate the involvement of these different pathways in the BMP4-induced osteogenesis of MDSCs. In studying the osteogenic differentiation of MDSCs induced by BMP4, it was also important to determine how this growth factor affected cell metabolic activity, and the involvement of the different pathways analyzed in this study. However, when BMP4 was added to the PM, the MDSC population used was unaffected. This may be explained by an inverse relationship between proliferation and differentiation, where molecules that promote differentiation may also prevent cell cycle reentry. Although MDSCs readily responded to BMP4 by undergoing osteogenic differentiation, they did not increase their proliferation. By using chemical inhibitors, it was determined that the viability of MDSCs was affected by inhibition of the PI3K pathway but not by inhibition of the p38 MAPK or ERK1/2 pathway. Activation of the PI3K/Akt signaling pathway by growth factors leads to the phosphorylation of the BCL-2 family member BAD, which in turn prevents apoptosis and promotes cell survival. 41, 42 Activation of the ERK1/2 pathway also follows a similar mechanism. 43 Reduced viability was thus expected after blockade of the PI3K signaling pathway with Ly294002 or inhibition of the ERK1/2 signaling pathway with PD98059. On the other hand, activation of p38 MAPK is known to induce exit from the cell cycle and to lead to the differentiation of various cell types. 44, 45 Its inhibition by SB203580 has increased the proliferation of mammalian cardiomyocytes, although these cells are considered terminally differentiated and incapable of proliferation. 46 In the MDSCs used in this study, reduced cellular viability was only seen with Ly294002 and has previously been reported in other adult muscle cells. 47 Inhibition of the ERK1/2 and p38 MAPK pathways may not play a significant role in the cellular viability of MDSCs, or a higher concentration of the inhibitors may be needed to have an effect.
The role of the ERK1/2, p38 MAPK, and PI3K pathways was also investigated with respect to the role they play in the osteogenic differentiation of MDSCs. Genes such as Alp, Runx2, and Osx were investigated, as they are key early indicators of osteogenic differentiation. The inhibition of the ERK1/2 pathway during BMP4 stimulation did not significantly affect osteogenic gene expression, although it showed a trend toward increasing Alp compared with BMP4 treatment only. It did, however, increase ALP activity after 3 days of stimulation with BMP4. This effect has been also shown in C2C12 cells and human MSCs, suggesting that high ERK activity negatively regulates BMP stimulation of ALP. 14, 17 In the present study, the effect of pathway inhibitors on matrix mineralization was also studied. Inhibition of the ERK1/2 pathway in BMP4-treated MDSCs affected mineralization by significantly increasing it, compared with BMP4 treatment only. The BMP4-induced synthesis of osteocalcin, a bonetype extracellular matrix protein, in MC3T3-E1 cells has been increased by inhibition of the ERK1/2 pathway with PD98059, 36 suggesting that the ERK1/2 pathway is a negative regulator of osteogenesis. The role of ERK1/2 as a negative regulator of matrix mineralization has been also recently shown in human MSCs in a 3D collagen type I culture 48 and in an in vivo calvaria model. 49 Interestingly, the present study showed that when the pathway was inhibited in BMP4-treated pellets for only 7 days and the pellets then cultured with BMP4 only, the increased mineralization was still evident at 21 days. This suggests that blocking the ERK1/2 pathway at early time points during osteogenesis may be important to promote mineralization. The continued increase in mineralization over time indicates that pretreatment of cells with PD98059 may be sufficient to promote bone formation, a technique that may be valuable in the development of novel bone tissue engineering approaches. From the results presented in this study, the ERK1/2 pathway was found to be a negative regulator of the BMP4-induced osteogenesis of MDSCs.
Studies investigating the role of the p38 MAPK pathway in osteogenic differentiation are at times conflicting. A report on the inhibition of p38 MAPK activity in C2C12 cells treated with BMP2 showed an increased osteogenic effect, suggesting an inhibitory role of p38 MAPK on osteogenesis. 29 In other studies that employed either BMP2 or BMP4 on primary calvarial osteoblasts, primary bone marrow osteoprogenitor cells, normal human osteoblasts, or the murine osteoblast line MC3T3-E1, it was found that p38 MAPK is necessary for BMP-induced osteogenic differentiation. [25] [26] [27] [28] 36, 50 Recently, it has been also found that the p38 MAPK pathway plays a positive role in BMP-induced Osx expression. 51, 52 In the present study on MDSCs, Alp and Osx gene expression was also shown to be dependent on p38 MAPK activation. Mineralization of MDSCs was decreased as a result of p38 MAPK inhibition, again suggesting that the p38 MAPK pathway is necessary for the osteogenic differentiation of MDSCs. This was further confirmed when the p38 MAPK pathway was inhibited in BMP4-treated MDSC pellets for only 7 days. Although a decrease in mineralization was evident at 14 days, mineralization recovered and approached that seen in MDSC pellets that received BMP4 only stimulation for 21 days. Hence, MDSCs that had the p38 MAPK pathway initially inhibited were able to undergo mineralization once the inhibition was removed.
The PI3K pathway has not been as widely studied as the MAPK pathways in BMP signaling, especially its role in matrix mineralization. In MDSCs, at the gene expression level, inhibition of the PI3K pathway increased the expression of Runx2 and Osx, whereas Alp gene expression was not significantly affected. At the protein level, ALP activity was significantly decreased when PI3K was inhibited in BMP4-treated cells. This decrease in BMP-stimulated ALP activity with Ly294002 is in accordance with previous studies utilizing BMP2 on human MSCs and mouse calvaria cells 15, 17 or endogenous BMPs, including BMP4, on human MSCs. 21 However, the nonsignificant effect of Ly294002 on Alp gene expression after BMP stimulation is not in accordance with previous studies. 17, 21 The reason why Ly294002 may not have had an effect on the expression of Alp, but decreased ALP activity, may be due to the timing of the assays. Gene expression was measured after 24 h of stimulation, whereas ALP activity at the protein level was measured after 3 days. The effect of Ly29402 on gene expression may have occurred earlier or later than 24 h and may have caused it to be different than the protein level. Another interesting finding in this study is that when MDSCs were cultured as pellets in OSM, the inhibition of the PI3K pathway significantly increased matrix mineralization when compared with BMP4 only treatment. This suggests that PI3K may play a negative role in matrix mineralization. This finding is in accordance with that seen in vascular smooth muscle cells, where Akt signaling was found to have an inhibitory activity on the matrix calcification of these cells. 53 Interestingly, inhibition of the PI3K pathway for only 7 days in MDSCs cultured as pellets in OSM did not affect mineralization. Thus, a continuous inhibition may be necessary. Taken together, the findings from this study suggest that PI3K may play a role in the BMP4-induced osteogenic differentiation of MDSCs, although more studies are necessary to elucidate its role in Alp gene expression. PI3K was found to play an important role in matrix mineralization and may be a potential target to promote bone formation in tissue engineering approaches.
Many chemical inhibitors are commercially available, although they may have different affinities for certain protein kinases. 54 The inhibitors PD98059, SB203580, and Ly294002 are commonly used in the literature and were thus selected for this study, although other inhibitors could be used in their place. 54 PD184352 and U0126 could be used instead of PD98059. SB202190 is structurally similar and has a similar specificity to SB203580. In addition to Ly294002, the PI3K pathway can also be inhibited by Wortmannin and Quercetin. Future studies on MDSCs could use these different chemical inhibitors to more clearly define the role of the ERK1/ 2, p38 MAPK, and PI3K pathways on BMP4-induced osteogenesis. It should also be noted that chemical inhibitors could affect more than one pathway because of cross-talk between pathways. ERK1/2, p38 MAPK, and PI3K have all been linked with BMP-activated Smads. 15, 17, 26, 55 As well, different cell types may respond differently to BMPs and pathway inhibitors. Thus, the role of these signaling pathways in BMP-induced osteogenesis is not a clearly defined process, but can be complicated by their individual and cooperative roles in the regulation of osteogenic markers.
This study was the first step toward understanding how BMP4 signals in MDSCs. By using well-established chemical inhibitors to the ERK1/2, p38 MAPK, and PI3K pathways, we demonstrated that the ERK1/2 pathway plays an inhibitory role in the osteogenic differentiation of MDSCs, especially in their mineralization. On the other hand, the p38 MAPK pathway plays an important stimulatory role in osteogenesis. Another interesting finding in this study is that the PI3K pathway may play an inhibitory role in the matrix mineralization of MDSCs. Future studies may involve preconditioning MDSCs with the ERK1/2 pathway inhibitor to increase their osteogenic differentiation in vitro and potentially enhance their ability to form bone in vivo. The inhibition of the PI3K pathway may also be a potential target. These studies will be especially useful to increase the matrix formation of cells that show less than optimal osteogenic potential. Therefore, further investigation into how the ERK1/2, p38 MAPK, and PI3K pathways affect MDSC differentiation in monolayer, pellet culture, or other 3D environments such as tissue engineering scaffolds is warranted, as it may identify novel therapeutic strategies for the development of stem cellbased therapies for bone tissue engineering.
